JP2004537581A - メラニン濃縮ホルモン拮抗物質 - Google Patents

メラニン濃縮ホルモン拮抗物質 Download PDF

Info

Publication number
JP2004537581A
JP2004537581A JP2003518580A JP2003518580A JP2004537581A JP 2004537581 A JP2004537581 A JP 2004537581A JP 2003518580 A JP2003518580 A JP 2003518580A JP 2003518580 A JP2003518580 A JP 2003518580A JP 2004537581 A JP2004537581 A JP 2004537581A
Authority
JP
Japan
Prior art keywords
acid
alanine
amino
arginine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003518580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537581A5 (enExample
Inventor
ベドナレク，マリア・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2004537581A publication Critical patent/JP2004537581A/ja
Publication of JP2004537581A5 publication Critical patent/JP2004537581A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2003518580A 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質 Pending JP2004537581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31092801P 2001-08-08 2001-08-08
PCT/US2002/026796 WO2003013574A1 (en) 2001-08-08 2002-08-02 Melanin-concentrating hormone antagonists

Publications (2)

Publication Number Publication Date
JP2004537581A true JP2004537581A (ja) 2004-12-16
JP2004537581A5 JP2004537581A5 (enExample) 2005-12-22

Family

ID=23204651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518580A Pending JP2004537581A (ja) 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質

Country Status (5)

Country Link
US (1) US7335723B2 (enExample)
EP (1) EP1416951A1 (enExample)
JP (1) JP2004537581A (enExample)
CA (1) CA2456964A1 (enExample)
WO (1) WO2003013574A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017069269A1 (ja) * 2015-10-23 2017-04-27 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
JP2017095443A (ja) * 2015-10-23 2017-06-01 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
US12011427B2 (en) 2019-12-11 2024-06-18 Inspirna, Inc. Methods of treating cancer

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049655A (en) * 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
CA2399509A1 (en) 2000-02-03 2001-08-09 Merck & Co., Inc. Melanin-concentrating hormone analogs
EP1485405A4 (en) 2001-05-31 2005-09-21 Merck & Co Inc MELANIN CONCENTRATING HORMONE ANALOG
JP2005527491A (ja) 2002-01-09 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド 選択的メラニン凝集ホルモンタイプ−１受容体アゴニスト

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017069269A1 (ja) * 2015-10-23 2017-04-27 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
JP2017095443A (ja) * 2015-10-23 2017-06-01 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
KR20180041243A (ko) * 2015-10-23 2018-04-23 후지필름 가부시키가이샤 환상 펩타이드, 어피니티 크로마토그래피 담체, 표지화 항체, 항체 약물 복합체, 및 의약 제제
US10703778B2 (en) 2015-10-23 2020-07-07 Fujifilm Corporation Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
KR102139057B1 (ko) 2015-10-23 2020-07-29 후지필름 가부시키가이샤 환상 펩타이드, 어피니티 크로마토그래피 담체, 표지화 항체, 항체 약물 복합체, 및 의약 제제
US12011427B2 (en) 2019-12-11 2024-06-18 Inspirna, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
EP1416951A1 (en) 2004-05-12
CA2456964A1 (en) 2003-02-20
US20040254338A1 (en) 2004-12-16
US7335723B2 (en) 2008-02-26
WO2003013574A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
US7335723B2 (en) Melanin-concentrating hormone antagonists
JP5254868B2 (ja) ソマトスタチン−ドーパミンキメラ類似体
US6967237B2 (en) Ghrelin analogs
CZ20041254A3 (cs) Peptidy uvolňující růstový hormon
TW200403253A (en) Ghrelin analogs
CN101267830B (zh) 生长激素促分泌物
JP4472256B2 (ja) ウロコルチンｉｉｉ及びその利用
ES2313978T3 (es) Proteinas urocortina y sus usos.
JP2007534613A (ja) レラキシンスーパーファミリーペプチド類似体
Erchegyi et al. Novel sst4-selective somatostatin (SRIF) agonists. 2. Analogues with β-methyl-3-(2-naphthyl) alanine substitutions at position 8
IL318194A (en) Methods for treating obesity with an MC4R agonist
JP2003522184A (ja) メラニン濃縮ホルモン類似体
US7273846B2 (en) Selective melanin-concentrating hormone type-1 receptor agonists
US7314861B2 (en) Melanin-concentrating hormone analogs
US7220720B2 (en) Melanin-concentrating hormone analogs
Audousset-Puech et al. Synthesis of the C-terminal octapeptide of pig oxyntomodulin. Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala: a potent inhibitor of pentagastrin-induced acid secretion
KR20020038400A (ko) 디썰파이드로 결합되는 환펩타이드형 화합물
KR20020038398A (ko) 헵타펩타이드형 화합물 및 그 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080421

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090203